A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
/in Dendritic Cells, International Publications, Ovarian CancerDendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
/in Dendritic Cells, International Publications, Ovarian CancerGenomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
/in Dendritic Cells, International Publications, Malignant MelanomaAssessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
/in Dendritic Cells, International Publications, Soft Tissue SarcomaBlood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerReview of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist
/in Hyperthermia, International PublicationsEvaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
/in Breast Cancer, Dendritic Cells, International Publications, Newcastle Disease VirusDendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de